ZAI LAB LIMITED Increase (Decrease) in Other Current Liabilities
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Other Current Liabilities of -$16.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was $1.24M, a 83.14% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was -$17.64M.
- ZAI LAB LIMITED increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was $11.52M, a 22.34% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was $9.18M.
- ZAI LAB LIMITED increase (decrease) in other current liabilities for fiscal 2025 was $4.75M.
- ZAI LAB LIMITED increase (decrease) in other current liabilities for fiscal 2024 was -$22.02M, a 211.17% decline from fiscal 2023.
- ZAI LAB LIMITED increase (decrease) in other current liabilities for fiscal 2023 was $19.81M, a 167.99% increase from fiscal 2022.
- ZAI LAB LIMITED increase (decrease) in other current liabilities for fiscal 2022 was $7.39M, a 75.48% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 3 month as first filed | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 6 month as first filed | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 9 month as first filed | Increase (Decrease) in Other Current Liabilities 12 month | Increase (Decrease) in Other Current Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$16.40M 10-Q · filed 2026-08-06 | -$4.88M derived: sum of 3 quarters · filed 2026-08-06 | $4.29M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$17.64M 10-Q · filed 2026-05-07 | -$6.12M derived: sum of 2 quarters · filed 2026-05-07 | $3.06M derived: sum of 3 quarters · filed 2026-05-07 | $10.39M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $11.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $20.70M derived: sum of 2 quarters · filed 2026-02-26 | $28.02M derived: sum of 3 quarters · filed 2026-08-06 | $4.75M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $9.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $16.51M derived: sum of 2 quarters · filed 2026-08-06 | -$6.77M 10-Q · filed 2025-11-06 | $8.06M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $7.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$15.95M 10-Q · filed 2026-08-06 | -$1.12M derived: sum of 3 quarters · filed 2026-08-06 | -$2.36M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$23.27M 10-Q · filed 2026-05-07 | -$8.44M derived: sum of 2 quarters · filed 2026-05-07 | -$9.69M derived: sum of 3 quarters · filed 2026-05-07 | -$11.09M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $14.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.59M derived: sum of 2 quarters · filed 2026-02-26 | $12.18M derived: sum of 3 quarters · filed 2026-02-26 | -$22.02M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.65M derived: sum of 2 quarters · filed 2025-11-06 | -$36.85M 10-Q · filed 2025-11-06 | -$17.27M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | -$1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$35.61M 10-Q · filed 2025-08-07 | -$16.02M derived: sum of 3 quarters · filed 2026-02-26 | -$9.04M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | -$34.20M 10-Q · filed 2025-05-08 | -$14.62M derived: sum of 2 quarters · filed 2026-02-26 | -$7.63M derived: sum of 3 quarters · filed 2026-02-26 | $1.20M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $19.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.57M derived: sum of 2 quarters · filed 2026-02-26 | $35.40M derived: sum of 3 quarters · filed 2026-02-26 | $19.81M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $6.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $15.82M derived: sum of 2 quarters · filed 2024-11-12 | $227.00K 10-Q · filed 2024-11-12 | $5.99M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $8.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$6.76M 10-Q · filed 2024-08-06 | -$997.00K derived: sum of 3 quarters · filed 2025-02-27 | $3.73M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$15.59M 10-Q · filed 2024-05-08 | -$9.83M derived: sum of 2 quarters · filed 2025-02-27 | -$5.10M derived: sum of 3 quarters · filed 2025-02-27 | $636.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.49M derived: sum of 2 quarters · filed 2025-02-27 | $16.23M derived: sum of 3 quarters · filed 2025-02-27 | $7.39M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $4.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $10.46M derived: sum of 2 quarters · filed 2023-11-07 | $1.63M 10-Q · filed 2023-11-07 | $11.18M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $5.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.10M 10-Q · filed 2023-08-07 | $29.51M 10-Q · filed 2022-08-09 | $6.45M derived: sum of 3 quarters · filed 2024-02-27 | -$1.04M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-03-31 | -$8.84M 10-Q · filed 2023-05-09 | -$11.12M 10-Q · filed 2022-05-10 | $714.00K derived: sum of 2 quarters · filed 2024-02-27 | -$6.77M derived: sum of 3 quarters · filed 2024-02-27 | -$402.00K derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $9.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.06M derived: sum of 2 quarters · filed 2024-02-27 | $8.44M derived: sum of 3 quarters · filed 2024-02-27 | $30.14M 10-K · filed 2024-02-27 | $19.46M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | -$7.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$1.12M derived: sum of 2 quarters · filed 2022-11-09 | $20.59M 10-Q · filed 2022-11-09 | $23.43M 10-Q · filed 2021-11-09 | $36.25M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $6.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $28.08M 10-Q · filed 2022-08-09 | $28.08M 10-Q · filed 2021-08-09 | $43.74M derived: sum of 3 quarters · filed 2023-03-01 | $34.06M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $21.71M 10-Q · filed 2022-05-10 | $37.37M derived: sum of 2 quarters · filed 2023-03-01 | $27.69M derived: sum of 3 quarters · filed 2023-03-01 | $33.80M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $5.99M derived: sum of 2 quarters · filed 2023-03-01 | $12.09M derived: sum of 3 quarters · filed 2023-03-01 | $10.68M 10-K · filed 2023-03-01 | -$10.98M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$9.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$3.57M derived: sum of 2 quarters · filed 2021-11-09 | -$4.98M 10-Q · filed 2021-11-09 | |||||
| 2020-06-30 | $6.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $4.70M 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | -$1.41M 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | $9.14M 10-K · filed 2022-03-01 | |||||||
| 2019-06-30 | $4.03M 6-K · filed 2020-09-11 | |||||||
| 2018-12-31 | $7.06M 10-K · filed 2021-03-01 | |||||||
| 2017-12-31 | $1.95M 20-F · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |